Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2013
10/15/2013US8557293 Sunscreen compositions for application to plants
10/15/2013US8557286 Method for producing a water-insoluble amorphous or partially amorphous controlled release matrix
10/15/2013US8557282 Extended release compositions comprising as active compound venlafaxine hydrochloride
10/15/2013US8557280 Stable pharmaceutical composition and methods of using same
10/15/2013US8557262 Divinyl ether derivatives capable of releasing active aldehydes and ketones and methods of use for perfuming surfaces
10/15/2013US8557259 Liquid preparation
10/15/2013US8557244 Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
10/15/2013US8557238 EG-VEGF nucleic acids and polypeptides and methods of use
10/15/2013US8557231 Biodegradable poly(beta-amino esters) and uses thereof
10/15/2013US8557230 Cosmetic compositions containing block copolymers, tackifiers and shine enhancing agents
10/15/2013CA2767092C Novel compounds, pharmaceutical compositions containing same and methods of use for same
10/15/2013CA2745020C Phytoestrogenic compositions for preventing or treating symptoms associated with menopause
10/15/2013CA2735294C N-(2-aminophenyl)-4-[n-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (ms-275) polymorph b
10/15/2013CA2731273C Processes and intermediates for preparing retroviral protease inhibitors
10/15/2013CA2728997C Pharmaceutical composition of levamlodipine or pharmaceutically acceptable salt thereof and .beta. receptor blocking agent, and use thereof
10/15/2013CA2717181C Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions
10/15/2013CA2697256C Cyclopropyl amide derivatives
10/15/2013CA2695556C Use of carolaction or derivatives thereof to prevent or treat bacterial biofilms
10/15/2013CA2667936C Amorphous form of n-{2-fluoro-5-[3-(thiophene-2-carbonyl)-pyrazolo [1,5-a]pyrimidin-7-yl]-phenyl}-n-methyl-acetamide
10/15/2013CA2629478C Staurosporine derivatives for use in alveolar rhabdomyosarcoma
10/15/2013CA2628476C Pharmaceutical for use in the treatment of ureterolithiasis
10/15/2013CA2623160C Piperidin-4-yl-pyridazin-3-ylamine derivatives as fast dissociating dopamine 2 receptor antagonists
10/15/2013CA2615676C N(arylalkyl)-1h-pyrrolopyridine-2-carboxamide derivatives, preparation and therapeutic use thereof
10/15/2013CA2615663C Cyclohexylamin isoquinolone derivatives as rho-kinase inhibitors
10/15/2013CA2614085C Pharmaceutical dosage form based on an osmotic active ingredient release system comprising an active ingredient combination of nifedipine and/or nisoldipine and an angiotensin ii antagonist
10/15/2013CA2611813C New regimens for oral monophasic contraceptives
10/15/2013CA2611668C Formulation of a thienopyridine platelet aggregation inhibitor
10/15/2013CA2608702C Ergoline derivatives and their use as chemokine receptor ligands
10/15/2013CA2604327C Pharmaceutical aerosol composition
10/15/2013CA2597055C A catheter lock solution comprising citrate and a paraben
10/15/2013CA2594770C 5-pyrrolidinylsulfonyl isatin derivatives
10/15/2013CA2594127C Pharmaceutical aerosol formulations for pressurized metered dose inhalers comprising a sequestering agent
10/15/2013CA2592170C Glycine derivative and use thereof
10/15/2013CA2578093C Composition containing fermentable polysaccharides
10/15/2013CA2570268C Use of acetyl l-carnitine for the preparation of a medicine for the treatment of neuropathic pain in diabetic patients
10/15/2013CA2567700C 3-triazolyl-galactoside inhibitors of galectins
10/15/2013CA2566326C Peritoneal dialysis solution
10/15/2013CA2561729C Skin beautifier
10/15/2013CA2549720C Cell transfecting formulations of small interfering rna, related compositions and methods of making and use
10/15/2013CA2544344C Pharmaceutical formulations of a quinolone antibiotic containing flavouring substances with improved pharmaceutical properties
10/15/2013CA2533926C Methods and compositions for producing antigenic responses
10/15/2013CA2529055C Improved absorption of fat-soluble nutrients
10/15/2013CA2522319C N-[(piperazinyl)hetaryl]arylsulfonamide compounds and derivatives thereof with affinity for the dopamine d3 receptor
10/15/2013CA2516322C Glycosaminoglycan-dnase combination therapy
10/15/2013CA2511523C Pharmaceutical formulation with an insoluble active agent for pulmonary administration
10/15/2013CA2487732C Cardiac glycosides to treat cystic fibrosis and other il-8 dependent disorders
10/15/2013CA2445655C Drug releasing anastomosis devices and methods for treating anastomotic sites
10/15/2013CA2359627C Multi-purpose acid compositions comprising three gras acids
10/15/2013CA2296434C Mutations in the myostatin gene cause double-muscling in mammals
10/10/2013WO2013152350A1 Myricanol derivatives and uses thereof for treatment of neurodegenerative diseases
10/10/2013WO2013152342A1 Anti-cancer mtor inhibitor and anti-androgen combination
10/10/2013WO2013152313A1 Compositions and methods for treating cancer and diseases and conditions responsive to growth factor inhibition
10/10/2013WO2013152299A2 Inhibitors of eif4a and derivatives of pateamine a with antiviral activity and use
10/10/2013WO2013152298A1 Compounds useful as inhibitors of atr kinase and combination therapies thereof
10/10/2013WO2013152272A1 ΑΖΑ-β-LACTAM COMPOUNDS AND METHODS OF USING
10/10/2013WO2013152269A1 Fused cyclopentyl antagonists of ccr2
10/10/2013WO2013152252A1 Combination anti-cancer therapy
10/10/2013WO2013152227A1 Embelin-based delivery system for water-insoluble active agents
10/10/2013WO2013152223A2 Methods for inhibiting viruses by targeting cathepsin-l cleavage sites in the viruses' glycoproteins
10/10/2013WO2013152206A1 Novel triazole compounds that modulate hsp90 activity
10/10/2013WO2013152198A1 Protein kinase c inhibitors and uses thereof
10/10/2013WO2013152193A2 Methods of treating proliferative disorders with malate or derivatives thereof
10/10/2013WO2013152170A1 Selective androgen receptor modulators
10/10/2013WO2013152165A1 Methods for treating cancer using pi3k inhibitor and mek inhibitor
10/10/2013WO2013152150A1 Heterocyclic compounds and their uses
10/10/2013WO2013152135A1 Substituted quinolines as bruton's tyrosine kinases inhibitors
10/10/2013WO2013152108A1 5ht1a agonist for treatment of high cholesterol
10/10/2013WO2013152063A1 Naphthyridinone derivatives as inhibitors of cytomegalovirus dna polymerase
10/10/2013WO2013152055A1 Method and composition for ameliorating the effects for a subject exposed to radiation or other sources of oxidative stress
10/10/2013WO2013152044A1 Use of pc-nsaids to treat and/or prevent pulmonary inflammation
10/10/2013WO2013152039A1 Compounds, compositions, and methods for modulating ferroptosis and treating excitotoxic disorders
10/10/2013WO2013152032A1 Compositions and methods for treating cancer
10/10/2013WO2013151994A1 Compositions and methods comprising toll like receptor (tlr) stimulating agents for prophylaxis and therapy for damage to dermal epithelium
10/10/2013WO2013151982A1 Methods and compounds useful in treating pruritus, and methods for identifying such compounds
10/10/2013WO2013151930A1 Bicyclic azaheterocyclobenzylamines as pi3k inhibitors
10/10/2013WO2013151923A1 Pyrimidinone carboxamides as inhibitors of endothelial lipase
10/10/2013WO2013151913A1 Tyrosine kinase inhibitor combinations and their use
10/10/2013WO2013151877A1 Pyrimidinedione carboxamide inhibitors of endothelial lipase
10/10/2013WO2013151876A1 Aldosterone synthase inhibitors
10/10/2013WO2013151832A1 Tetrahydropyrrolothiazine compounds
10/10/2013WO2013151774A1 Combination therapy with an anti - hyaluronan agent and a tumor - targeted taxane
10/10/2013WO2013151769A1 Methods for modulating plant response to environmentally-induced stress
10/10/2013WO2013151758A2 Methods for increasing cftr activity
10/10/2013WO2013151754A1 Ibuprofen solid oral dosage composition comprising a methacrylic acid copolymer
10/10/2013WO2013151744A1 Materials and methods for treatment of cystic fibrosis and for induction of ion secretion
10/10/2013WO2013151719A2 Fluorinated oxazolidinone derivatives
10/10/2013WO2013151707A1 Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
10/10/2013WO2013151699A1 Composition and method for corneal proliferation
10/10/2013WO2013151671A1 Modified polynucleotides for the production of cosmetic proteins and peptides
10/10/2013WO2013151638A1 Novel compositions of combinations of non-covalent dna binding agents and anti-cancer and/or anti-inflammatory agents and their use in disease treatment
10/10/2013WO2013151597A2 (1,2,3-triazolyl) sulfonyl derivatives
10/10/2013WO2013151595A1 Improved adjuvant system for oral vaccine adminstration
10/10/2013WO2013151584A1 Compound comprising a mao targeting/ seeker moiety for treating human gliomas
10/10/2013WO2013151518A1 Capsule formulations comprising ceftibuten
10/10/2013WO2013151517A1 Tablet formulations comprising cefpodoxime proxetil and clavulanic acid
10/10/2013WO2013151516A1 Film tablet formulations comprising cefuroxime axetil and clavulanic acid
10/10/2013WO2013151490A1 Methods and compounds for treating diseases
10/10/2013WO2013151450A1 Aromatic imidazolidinone derivatives and their use in the treatment of diseases of bacterial nature
10/10/2013WO2013151382A1 Escherischia coli strain for simultaneously providing two different anticancer substances
10/10/2013WO2013151341A1 Injectable composition comprising phosphatidylcholine and method for preparing thereof
1 ... 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 ... 7860